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Objectives. The objective of this study was to obtain prelimi-
nary data an She relative clinical utility of direct coronary
angioplasty compared with that of intravenous thrombolytic ther-
apy for patients with acute myocardial infarction
.
Background. The relative merits of intravenous thrombolytic
therapy and direct coronary angioplasty as treatment for acute
myocardial Infarction are incompletely understood, and random-
ised trials of these treatments have been extremely limited
.
l4etheds . One hundred patients with ST segment elevation
presenting to a single high volume interventional center within 6 h
of the onset of chest pain were randomized to receive either
streptokinase (1 .2 million U intravenously over 1 h) or immediate
catbeterization and direct coronary angioplasty . Patients were
excluded for age ?75 years, prior bypass surgery, Q wave
Infarction In the region of ischemia or excessive risk of bleeding .
All patients were then treated with aspirin (325 mg orally/day) and
heparin (1,000 U intravenously/h) for 48 h until catheterization
was performed to determine the primary study end point, namely,
The use of intravenous thrombolytic therapy in patients with
acute myocardial infarction has resulted in a 13% to 50%
decrease in the short-term mortality rate (1-3) for those who
are eligible . Direct coronary angioplasty may also be used to
reestablish vessel patency in this setting (4,5) and may be
suitable for a broader array of patients but probably results
in a greater delay to treatment and a higher cost than
intravenous thrombolytic therapy . Angioplasty has the ad-
ditional potential advantage of lessening the severity of the
infarct-producing stenosis to a greater degree than is
achieved with thrombolytic therapy (6) and, therefore, po-
tentially leading to greater recovery of left ventricular func-
tion, although this is controversial (6-9) . The importance of
restitution of full Thrombolysis in Myocardial Infarction
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infarct-related artery patency at 48 h . Secondary end points were
tn-hospital death, left ventricular eleettou fraction at 48 h and
time to treatment .
Results. There was no difference in the baseline characteristics
of the two treatment groups. Overall patient age was 56 ± 10
years, 83% of patients were male, I I % had prior Infarction, 40
had anterior Infarction and 97% were in Killip class I or II .
Although time to treatment was delayed in the angioplasty group
(238 t 112 vs
. 179 t 98 min, p = 0 .005), there was no difference
in 48-h infarct-related artery patency or left ventricular ejection
traction (patency 74% vs . %; ejection fraction 59 ± 13% vs
.
57 t 13% ; angioplasty vs
. streptokinase, p = NS for both) . There
were no major bleeding events, and the mortality rate with
angloplasty (6%) and streptokinase (2%) did not differ (p = NS) .
Coirciusions . These results suggest that Intravenous thrombo-
lytic therapy might bt; preferred over coronary angioplasty for
most patients because of the often shorter time to treatment .
(J Am Call Cardioi 1993;22:376-80)
(TIMI) grade 3 flow (8) compared with TIMI grade 2 flow,
although both are associated with vessel "patency," was
recently noted (10) . Although in-hospital survival after direct
angioplasty appears to be similar to that achieved with
thrombolytic therapy, differences in the patient groups stud-
ied make comparison difficult (5,11) .
Direct coronary angioplasty might be considered either in
the setting where it can be applied quickly as an alternative
to intravenous thrombolytic therapy or when intravenous
thrombolytic therapy is believed to be contraindicated . This
report describes the results of a randomized trial of direct
coronary angioplasty compared with intravenous throiabo-
lytic therapy in an attempt to determine the appropriate role
of direct coronary angioplasty in the treatment of acute
myocardial infarction .
Methods
Study patients . Consecutive patients presenting with
acute myocardial infarction to Unic6r Hospital between
February 1989 and September 1989 were recruited . Unicbr
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Figure 1 . Study protocol outline showing treatments and end points .
ASA = aspirin
; Cath = cardiac catheterization : IV SK = intrave-
nous streptokinase ; LVEF = left ventricular ejection fraction ;
PTCA = direct coronary angioplasty ; Rx = trealment ; 1 ° = primary ;
2° = secondary .
Hospital, located in Sao Paulo, Brazil, is a busy tertiary
referral center for patients with acute coronary heart dis-
ease. Before the start of this study, investigators at Unic6r
Hospital had performed 1,600 angioplasty procedures and
treated 1,100 patients with intravenous thrombolytic therapy
in the setting of acute myocardial infarction . Patients were
eligible for inclusion for this study if they presented with
chest discomfort typical of coronary ischemia of 20 min to
6 h duration and had electrocardiographic ST segment
elevation ? I mm in two or more contiguous leads. Patients
were excluded for any of the following : 1) relief of chest pain
by sublingual nitroglycerin, 2) history of stroke within 6
months, 3) history of major surgery or trauma within 6
months, 4) history of abnormal bleeding so as to contraindi-
cate the use of thrombolytic therapy, 5) history of prior
coronary artery bypass graft surgery; 6) age X75 years, and
7) prior Q wave myocardial infarction in the same infarct
distribution as the index infarction . This protocol was ap-
proved by the Institutional Review Board at Unic6r Hospi-
tal .
Study protocol (Fig. 1). After patients had given written
informed consent, they were randomized to receive either
1 .2 million U of intravenous streptokinase over I h or
immediate cardiac catheterization with direct angioplasty to
the infarct-related vessel . Randomization was performed
using a closed envelope system without patient stratification .
Patients eligible for the study but not randomized were
characterized in a registry log . Patients randomized to re-
ceive intravenous streptokinase also were treated with aspi-
rin (325 mg orally/day) and intravenous heparin (1,000 U/h)
until the time of the 48-h catheterization. Patients random-
ized to direct angioplasty had that procedure performed and
were then treated also with aspirin (325 mg/day) and intra-
venous heparin (1,000 U/h) . At 48 h after hospital admission,
all patients were taken to the cardiac catheterizatioh labora-
tory for catheterization to assess infarct artery patency and
left ventricular ejection fraction . Thereafter, all patients
were treated with continued aspirin and diftiazem (60 mg
nrally three times daily) .
Angiography. Angiography was routinely performed us-
ing the brachial approach . For those patients randomized to
direct angioplasty, of heparin (10,000 U) was given after
accessing the brachial artery. A single injection of the
noninfarct-related artery or arteries was followed by multi-
ple injections to visualize the infarct-related artery in orthog-
onal views . Infarct artery patency was defined as TIMI grade
2 or 3 flow (12) . Infarct arteries were prospectively charac-
terized as being either well suited or not well suited for
angioplasty . Arteries were defined as not well suited for
direct angioplasty if they met any of the following criteria
(7) : I) y50% stenosis in the left main coronary artery ;
2) _7.i% lesions in both the proximal left circumflex and
proximal left anterior descending coronary arteries ; 3) se-
vere, diffuse, multilesion or multivessel disease ; 4) cardio-
genic shock, defined as systolic blood pressure <90 mm Hg
with clinical signs of multiorgan hypoperfusion ; and 5) an
unidentifiable infarct-related artery . However, angioplasty
was attempted even on arteries not believed to be well suited
for that procedure .
Left ventricular analysis . Global left ventricular ejection
fraction was determined from the 48-h ventriculograms using
the area-length method (13) .
Coronary angioplasty . Coronary angioplasty was rou-
tinely performed using the brachial approach. Most com-
monly, 4 .3F shaft polyethylene terephthalate balloons were
used, employing two to four inflation to a maximum of 8 to
10 atm for 60- to 90-s intervals . The procedure was consid-
ered successful if <50% stenosis and TIMI grade 2 or 3 flow
resulted .
Follow-up . Patients were followed up for the occurrence
of comorbid complications until the time of hospital dis-
charge. Overall mortality, need for blood product transfu-
sion, major bleeding . recurrent ischemia (defined as at least
two of the following: angina, ST segment changes consistent
with new ischemia or reelevation of serum creatine kinase
levels with isoenzyme confirmation) and the time and peak
creatine kinas -MR levels were noted . The standard ap-
proach for the treatment of recurrent ischemia in either
randomized group was urgent cardiac catheterization and
angioplasty, if necessary . In general, blood prodact trarr~ ;fii-
sion was considered to be indicated for hematocrit <30% or
hemoglobin <10 trrlg/dl .
Statistical analysis . All data are reported as mean value
SD, unless otherwise noted . Comparison of dichotomous
variables between treatment groups was made using chi-
square analysis . Comparison of continuous variables be-
tween treatment groups was made using Student i test
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Table 1
. Baseline Patient Characteristics
Data are expressed as mean value 7 SD or number or percent of patients .
CAD - coronary artery disease ; Inf = inferior : tat = lateral ; MI = myocardial
infarction
; PTCA = direct coronary angioplasty ; SK = intravenous streptoki-
nase.
analyses . A p value !5 0.05 was considered significant . The
primary end point of this study was infarct-related artery
patency at the 48-h study . Prespecified secondary end points
included in-hospital death, left ventricular ejection fraction
at 48 h, blood product transfusion and the time to treatment .
The prior correlation of delayed infarct vessel patency and
early postinfarction left ventricular ejection fraction with
long-term survival (14,15) was considered to justify the use
of 48-h patency as the primary end point of this study . It was
recognized that this was a preliminary study that did not
have the statistical power to adequately assess differences in
major clinical outcomes . Two post-hoc analyses were per-
formed: I) comparison of major end points excluding pa-
tients "not well suited" for angioplasty to minimize any bias
originating from inclusion of these patients (whose charac-
teristics could not be ascertained before randomization)
while excluding patients with contraindications to thrombo-
lytic therapy ; and 2) comparison of left ventricular ejection
fraction only for patients with anterior infarction (because
right anterior oblique angiography may incompletely assess
this variable in patients with large lateral wall motion abnor-
malities).
Results
Baseline patient characteristics. The presenting charac-
teristics of the patients randomized in the two study groups
are enumerated in Table 1 . The two study groups did not
differ with regard to age, history of prior myocardial infarc-
tion, Killip class or location of infarction . Patients random-
ized to intravenous streptokinase, however, were treated
earlier (179 ± 98 vs
. 238 ± 112 min, p = 0.005). Nine
potentially eligible patients were not randomized for the
following reasons
: 1) ongoing cardiogenic shock or prior
cardiac arrest (n = 4), 2) referring physician referral (n = 3)
.
and 3) patient refusal (n = 2) .
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Table 2 . Infarct-Related Artery Patency Results 48 Hours
After Angioplasty
Data are expressed as mean value
±
SD or percent of patients . CK-MB =
creatine kinase MR isoenzyme ; LVEF = left ventricular ejection fraction ;
other abbreviations as in Table I .
Suitability for direct coronary angioplasty . Forty (80%) of
the 50 patients randomized to angioplasty were deemed to be
well suited for direct angioplasty and 10 patients (20%) were
believed to be not well suited for that procedure . The
reasons that patients were judged to be not well suited for
angioplasty were as follows : 1) ?75% lesions in both the
proximal left anterior descending and left circumflex coro-
nary arteries (n = 11) ; 2) cardiogenic shock (n = 3) ; 3) X50%
stenosis in the left main coronary artery (n = 2) ; and
4) severe, diffuse, multilesion or multivessel disease (n = 2) .
Immediate results of coronary angioplasty . Coronary an-
gioplasty was successful in 40 (80%) of 50 patients . Emer-
gency bypass surgery was required in 2 (4%) of 50 patients .
Angioplasty was successful in 36 (90%) of 40 patients be-
lieved to be well suited and 4 (40%, p < 0.001) of 10 patients
believed to be not well suited for the procedure .
Infarct-related artery patency at 48 h (Table 2). Forty-
eight hour infarct-related artery patency by TIMI grade is
shown in Table 2. The overall patency rates (TIMI grade 2 or
3 flow) did not differ . If the patients classified as not well
suited for angioplasty were excluded, then patency in the
angioplasty group would have been 87 .5% (p = NS vs. the
streptokinase group).
Secondary end points. There were three deaths (6%) in
the patients randomized to coronary angioplasty and one
death (2%) in the patients randomized to intravenous strep-
tokinase (p = NS) . The causes of death in the angioplasty
group were 1) cardiogenic shock 7 days after successful left
anterior descending coronary artery angioplasty in a patient
with prior inferior wall myocardial infarction ; 2) cardiogenic
shock after unsuccessful ostial left anterior descending cor-
onary artery angioplasty in a patient with prior inferior wall
myocardial infarction, whose stenosis could not be treated
without provoking extreme hypotension as a result of the
stenosis location
; 3) emergency bypass surgery in a patient 2
days after unsuccessful angioplasty of a highly calcified left
anterior descending artery stenosis . The single patient in the
intravenous streptokinase group who died of heart failure
during the hospital stay had successful reperfusion at 48 h,
but with a previous large anterior wall myocardial infarction .
PTCA p
Value SK
Patency (90 min) (96)
80 - -
Patency (48 h) (%) 74 NS
80
LVEF at 48 h (%) 59 ± 13 NS 57 ± 13
Peak CK-MB (U) 83 .4 ± 70.1 0.05 56.8 ± 34 .3
Time to CK-MB peak (h) 14 .4 ± 5
.9 NS :5 .5 ± 5.5
Major bleeding events (%) 0 NS
0
Blood product transfusion (96) 0 NS
0
Mortality (%) 6 NS 2
PTCA P Value
SK
Patients (no.)
50
50
Age (yr) 57 ± 10
NS 55 :t 10
Male (%) +K`
NS 86
Diabetic (96) 12 NS 10
Previous angina (%) 38 NS
34
Previous Ml (%)
6 NS 16
Anterior M1(R6)
34 NS
46
Inf/iat MI (%) 66 NS
54
Time to treatment (min) 238 ± 112
0
.005
179 ± 98
Killip class I-It (96)
94 NS 100
Killip class III-IV (°k)
6 NS 0
Multivessel CAD
(%)
40 Nc~ 32
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Left ventricular ejection fraction . There was no differ-
ence in the left ventricular ejection fraction at 48 h between
the two group, (angioplasty 59 ± 13%, streptokinase 57
13%, p = NS). For patients with anterior infarction, ejection
fraction was 56 ± 18% in the angioplasty group and 54 t
13% in the streptokinase group (p = NS) .
Blood product transfusion . No patients in either group
required blood product transfusion .
Time to treatment. As noted, the time to treatment with
coronary angioplasty was longer than that with intravenous
streptokinase (Table 1) .
Recurrent ischemia . Recurrent ischemia occurredin four
patients (8%) randomized to direct coronary angioplasty .
Two patients (4%) were managed medically, one (2%) un-
derwent repeat angioplasty and one (2%) was referred for
bypass surgery . Within *l a group of patients randomized to
streptokinase, recurrent ischemia occurred in five patients
(10!) and urgent angioplasty was successfully performed in
three (75%) of four patients in whom it was attempted .
Delayed coronary angioplasty (performed between 5 and 10
days after presentation) was performed sua:essrully in 19
(95%) of 20 streptolinase treated patients in whom it was
attempted . Elective coronary ' ery bypass surgery was
performed in 6 streptokinase-treated patients (15%) because
of three-vessel disease or anatomy unsuitable for coronary
angioplasty .
Discussion
For patients equally eligible for intravenous thrombolytic
therapy or direct coronary angioplasty or for patients whose
heightened risk of hemorrhage excludes them from consid-
eration of intravenous thrombolytic therapy, the role of
direct angioplasty remains to be defined . Prior nonrandom-
ized studies (4-6,11) have suggested equal or better coro-
nary artery patency with angioplasty, but the inherent time
delay in most clinical settings and heightened cost of keeping
many catheterization laboratories available for around the
clock treatment of many patients with acute myocardial
infarction with angioplasty would seem to favor application
of intravenous thrombolytic therapy to all patients who are
eligible.
Comparison with previous preliminary studies . Several
other small-scale randomized trials comparing direct coro-
nary angioplasty with thrombolytic therapy of patients with
acute myocardial infarction were performed in the same
general time frame as this study but have not been published
in full . Thus, DeWood et al . (16) randomized 54 patients
within 6 h of onset of chest pain to either direct coronary
angioplasty or intravenous recombinant tissue-type plasmin-
ogen activator (rt-PA) . Infarct-related artery patency at
90 min was 74% in patients randomized to rt-PA and 67% in
patients randomized to angioplasty . However, if one ex-
cludes 6 of 27 patients allocated to angioplasty because of
anatomy poorly suited for that procedure, the angioplasty
success rate in the remaining patients was 86% . There was
no difference between the two groups of randomized patients
with regard to the other primary end point of rest and
exercise ejection fraction measured 2 months after infarc-
tion . Analysis in that study (16) was confounded by the large
numbers of patients crossing oa er to angioplasty from the
tPA randomized arm . Gibbons et al . (17) randomized 103
patients presenting with ST segment elevation infarction
within 12 h of symptom onset to direct coronary angioplasty
or rt-PA given intravenously . There was no difference be-
tween groups in the primary study end point of myocardial
salvage assessed by acute and late tomographic imaging with
technetium-99m-sestamibi . Zijlstra et al . (18) reported re-
sults from 56 randomized patients and noted superior infarct-
related artery patency and ejection fraction in the angio-
plasty group, but these results were considered preliminary .
The results of the present study support the results of these
other small randomized trials, showing in general no major
difference in infarct-related artery patency or follow-up left
ventricular function, thus considerably strengthening the
overall assessment of general equivalence of these two forms
of therapy .
Limitations of the present study . The present study has
several limitations. 1) Similar to other reported randomized
trials addressing this issue, our study is underpowered to
detect differences in infarct-related artery patency and, to a
greater extent, clinical events . If one were to assume an 80%
infarct artery patency rate in patients given intravenous
thrombolytic therapy and if one were to assume a 90%
patency rate with coronary angioplasty, a study sample of
438 patients would be required to have a power of 0 .80 at
p = 0 .05. 2) The measurement in this study of left ventricular
ejection fraction at 48 h does not allow for full recovery from
myocardial "stunning" (15,19) . Therefore, the impact of
differences of overall or relative vessel ;latency between
these two modes of therapy on left ventricular myocardial
recovery may not he completely ascertained . 3) By protocol.
our study used "intention to treat" analysis, wherein angio-
plasty was performed in all patients randomized to this
treatment, regardless of coronary anatomy. This is not the
way clinical medicine is practiced and alternative forms of
revascularization certainly might have been considered in
those patients not appearing to be well suited for coronary
angioplasty
. if one were to eliminate the results from those
patients whose anatomy was not judged to be well suited to
angioplasty, then angioplasty was successful in 90% of
attempts . 4) This study was performed in an era jus' before
the routine surveillance of the adequacy of heparin anti-
coagulation in the catheterization laboratory by means of
measuring ai.tivated clotting times, as is now routine
. Strict
attention to the adequacy of heparin therapy (20) might have
improved the results with coronary angioplasty .
Conclusions . These results suggest that intravenous
thrombolytic therapy might be preferred over coronary
angioplasty for most patients because of the inherent time
delay aad probable increased expense with angioplasty but
JACC Vol . 22, No . 2
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that coronary angioplasty might quite rationally be applied
when the risk of bleeding is high and reperfusion therapy is
otherwise indicated .
We are grateful for the expert secretarial assistance provided by Patti
Durnwald.
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